Gems from the poster halls yielded some fascinating novel approaches and new twists on old targets
In this latest post ASH review, we explore some intriguing early developments from several small and large companies alike, explain why they matter and why we should be interested in them.
Sometimes the wisdom of the crowds isn’t always the best indicator of what’s coming down the pike in terms of oncology pipelines.
Part of our cunning plan this year involved going to ‘off Broadway’ sessions where we thought others would skip in favour of a more obviously popular session (the ones in the big halls) and merrily tweet them so you could easily follow along in parallel while the smaller rooms rapidly filled up and quietly closed to those desperately trying to get in late.
Our selections here include several gems from the poster halls (imagine trying to just pick a few highlights out of 4,000 poster options?!), as well as a couple of oral presentations that were missed by many – not surprising given how jam-packed the schedule was with double and even triple choices of selections in parallel to choose from!
Curious to find out more about our latest coverage and get a heads up on additional insights from our post ASH analysis and commentary?Subscribers can log-in or you can click to gain access to BSB Premium Content.
Orlando bound for ASH!
What is old is new again…
I have that distinct feeling of deja vu with the ASH asbtract drop yesterday on several fronts. It’s quite a few years now since we wrote about the runners and riders in the BTK/PI3K race to market in CLL and by weird coincidence a topic I was covering by interview yesterday on the RAS pathway came up in one of the first ASH asbtracts I was reading, which was rather spooky. Clearly Halloween came slightly late to Florida this year!
So how do all these disparate topics hang together and why are we excited about a small cap biotech company that is largely under many people’s radar?
They have some unexpected unifying threads…
To learn more from our oncology coverage and get a heads up on insights from the first of first ASH19 Previews, subscribers can log-in or you can click to gain access to BSB Premium Content.